Pravafen + Pravastatin + Fenofibrate
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Combined Hyperlipidemia
Conditions
Combined Hyperlipidemia
Trial Timeline
Apr 1, 2007 → Jul 1, 2009
NCT ID
NCT00459745About Pravafen + Pravastatin + Fenofibrate
Pravafen + Pravastatin + Fenofibrate is a phase 3 stage product being developed by Shionogi for Combined Hyperlipidemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00459745. Target conditions include Combined Hyperlipidemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00459745 | Phase 3 | Completed |
Competing Products
6 competing products in Combined Hyperlipidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| zonisamide | Eisai | Pre-clinical | 23 |
| Dalpicilib + Abiraterone Acetate (II) + Androgen Deprivation Therapy + Prednisone | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Tremelimumab + Durvalumab + Gemcitabine + Cisplatin | AstraZeneca | Phase 2 | 52 |
| Vaxelis™ | Merck | Approved | 85 |
| Leios/Alesse | Pfizer | Pre-clinical | 22 |
| Sodium phenylbutyrate | Zevra Therapeutics | Phase 1 | 25 |